Download our case study to learn how the UK’s Cell and Gene Therapy Catapult developed an efficient and scalable process for adeno-associated virus (AAV) production, with support from Thermo Fisher Scientific.
As part of the UK’s Cell and Gene Therapy Catapult’s (CGT Catapult) work to support innovation in cell and gene therapies, their team needed to establish a robust viral vector workflow. To maximize viral vector output for clinical and commercial manufacturing applications, CGT Catapult sought to build a process using reliable products and scalable solutions, backed by access to industry expertise, to help navigate production challenges.
In this case study we explore how CGT Catapult developed a streamlined, optimized viral vector workflow to drive cell and gene therapy innovation forward.
Download our case study to learn about:
- Challenges associated with maximizing viral vector output
- Building an optimized, scalable viral vector workflow
- How CGT Catapult leveraged Thermo Fisher Scientific’s extensive product portfolio and expertise to create a process for AAV production